Skeletal formula of moclobemide, the prototypical .<unk> s have been found to be effective in the treatment of panic disorder with agoraphobia, social phobia, atypical depression or mixed anxiety disorder and depression, bulimia, and post-traumatic stress disorder, as well as borderline personality disorder, and Obsessive Compulsive Disorder (OCD).<unk> s appear to be particularly effective in the management of bipolar depression according to a retrospective-analysis from 2009. There are reports of<unk>  efficacy in obsessive-compulsive disorder (OCD), trichotillomania, body dysmorphic disorder, and avoidant personality disorder, but these reports are from uncontrolled case reports.<unk> s can also be used in the treatment of Parkinson's disease by targeting MAO-B in particular (therefore affecting dopaminergic neurons), as well as providing an alternative for migraine prophylaxis. Inhibition of both MAO-A and MAO-B is used in the treatment of clinical depression and anxiety.<unk> s appear to be particularly indicated for outpatients with dysthymia complicated by panic disorder or hysteroid dysphoria Newer<unk> s such as selegiline (typically used in the treatment of Parkinson's disease) and the reversible<unk>  moclobemide provide a safer alternative and are now sometimes used as first-line therapy.
Monoamine oxidase inhibitor
Acetylcholinesterase inhibitor
Dopamine antagonist
Enkephalinase inhibitor
Monoamine reuptake inhibitor
Norepinephrine reuptake inhibitor
Glycine reuptake inhibitor
Opioid antagonist